Jan Koedam

407 total citations
9 papers, 222 citations indexed

About

Jan Koedam is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Jan Koedam has authored 9 papers receiving a total of 222 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Hematology. Recurrent topics in Jan Koedam's work include CAR-T cell therapy research (4 papers), Biosimilars and Bioanalytical Methods (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Jan Koedam is often cited by papers focused on CAR-T cell therapy research (4 papers), Biosimilars and Bioanalytical Methods (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Jan Koedam collaborates with scholars based in Netherlands and Germany. Jan Koedam's co-authors include Martin Wermke, Marc Cartellieri, Armin Ehninger, Maria-Elisabeth Goebeler, Gerhard Ehninger, Sabrina Kraus, Carla Kreissig, Jan Moritz Middeke, Malte von Bonin and Martin Bornhäuser and has published in prestigious journals such as Blood, Cancer Research and Annals of Oncology.

In The Last Decade

Jan Koedam

8 papers receiving 219 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Koedam Netherlands	6	173	83	69	54	53	9	222
Rebecca Epperly United States	7	171 1.0×	83 1.0×	40 0.6×	59 1.1×	29 0.5×	30	241
Marion Subklewe Germany	10	212 1.2×	71 0.9×	66 1.0×	40 0.7×	35 0.7×	24	257
Haven R. Garber United States	9	162 0.9×	82 1.0×	45 0.7×	42 0.8×	25 0.5×	20	245
Walid Warda France	7	132 0.8×	82 1.0×	42 0.6×	42 0.8×	34 0.6×	8	222
Kathleen Ruehle United States	8	212 1.2×	78 0.9×	121 1.8×	30 0.6×	33 0.6×	24	291
Ko Kudo Japan	6	160 0.9×	76 0.9×	26 0.4×	57 1.1×	83 1.6×	25	227
Marion Subklewe Germany	6	180 1.0×	86 1.0×	114 1.7×	36 0.7×	26 0.5×	36	276
Miriam Sánchez‐Escamilla Spain	5	193 1.1×	56 0.7×	36 0.5×	72 1.3×	50 0.9×	13	239
Peter Gambell Australia	6	136 0.8×	91 1.1×	118 1.7×	46 0.9×	25 0.5×	11	264
Robert Moot United States	7	144 0.8×	102 1.2×	53 0.8×	98 1.8×	24 0.5×	12	230

Countries citing papers authored by Jan Koedam

Since Specialization

Citations

This map shows the geographic impact of Jan Koedam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Koedam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Koedam more than expected).

Fields of papers citing papers by Jan Koedam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Koedam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Koedam. The network helps show where Jan Koedam may publish in the future.

Co-authorship network of co-authors of Jan Koedam

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Koedam. A scholar is included among the top collaborators of Jan Koedam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Koedam. Jan Koedam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Wermke, Martin, Stephan Metzelder, Sabrina Kraus, et al.. (2023). Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML. Blood. 142(Supplement 1). 3465–3465. 21 indexed citations

Ehninger, Gerhard, Sabrina Kraus, Elisa Sala, et al.. (2022). Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML. Blood. 140(Supplement 1). 2367–2368. 27 indexed citations

Wermke, Martin, Sabrina Kraus, Armin Ehninger, et al.. (2021). Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood. 137(22). 3145–3148. 117 indexed citations

Ehninger, Armin, Julia Riewaldt, Kristin Franke, et al.. (2021). Abstract 1506: Expansion kinetics and cytokine profiles of UniCAR-T-CD123, a rapidly switchable two-component CAR-T therapy, in patients with relapsed/refractory AML. Cancer Research. 81(13_Supplement). 1506–1506.

Veeger, Nic J.G.M., Marinus van Marwijk Kooy, Aart Beeker, et al.. (2013). Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leukemia Research. 37(8). 877–882. 24 indexed citations

Lokhorst, Henk M., Corien Eeltink, Gerwin Huls, et al.. (2010). Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program. Clinical Lymphoma Myeloma & Leukemia. 10(2). 138–143. 16 indexed citations

Wengström, Yvonne, et al.. (2006). Women's experience and knowledge of adjuvant endocrine therapy (AET) for early breast cancer (BC) : a European survey. Annals of Oncology. 17. 99–99. 4 indexed citations

Hoogenhout, J., et al.. (1991). Radiosensitivity of different human tumor lines grown as xenografts determined from growth delay and survival data. Lung Cancer. 7(4). 277–277. 11 indexed citations

Erp, P.E.J. van, et al.. (1984). Fucosyl Glycopeptide Profiles of Keratinocytes from Various Epithelial Tissues of the Rabbit in Relation to Differentiation In Vivo and In Vitro. Journal of Investigative Dermatology. 83(5). 359–362. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact